Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
19 Outubro 2023 - 9:00AM
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will
host a conference call with Patrick Holt, President & CEO, and
members of Amarin’s senior management team to discuss the Company’s
third quarter 2023 financial results on Wednesday, November 1st,
2023 at 8:00 a.m. ET.
To enhance engagement with the company’s shareholder base and
facilitate connections with its investors, Amarin is partnering
with Say Technologies to allow retail and institutional
shareholders to submit and upvote questions, a selection of which
will be answered by Amarin management during the earnings call.
Starting on October 19th at 8:00 am ET, all shareholders can
submit questions by visiting:
https://app.saytechnologies.com/amarin-2023-q3. This Q&A
platform will remain open until 24 hours before the start of the
earnings call. Shareholders can email
support@saytechnologies.com for any support inquiries.
The conference call with management will follow
the release of the Company’s third quarter 2023 financial results
in the pre-market hours.
Conference Call and Webcast Information:Access
to the live call:Go to the investor relations section of the
Company's website at www.amarincorp.comDial in within the
United States: 877-545-0523International dial in:
973-528-0016Access Code: 991868
Access to replay:Dial in within the United States:
877-481-4010International dial in: 919-882-2331 Access Code: 49172A
replay of the call will also be available through the Company's
website shortly after the call.
About
Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our foundation
in scientific research to our focus on clinical trials, and now our
commercial expansion, we are evolving and growing rapidly. Amarin
has offices in Bridgewater, New Jersey in the United States, Dublin
in Ireland, Zug in Switzerland, and other countries in Europe as
well as commercial partners and suppliers around the world. We are
committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and
advancing the treatment of that risk.
Availability of Other Information About
Amarin
Amarin communicates with its investors and the public using the
company website (www.amarincorp.com) and the investor relations
website (investor.amarincorp.com), including but not limited to
investor presentations and FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact
Information Investor
Inquiries: Jordan ZwickAmarin Corporation
plc IR@amarincorp.com (investor
inquiries) Media Inquiries: Mark MarmurAmarin
Corporation plcPR@amarincorp.com (media inquiries)
Amarin (NASDAQ:AMRN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Amarin (NASDAQ:AMRN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024